TY - JOUR
T1 - A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site
AU - Tsuya, Asuka
AU - Kurata, Takayasu
AU - Tamiya, Akihiro
AU - Okamoto, Isamu
AU - Ueda, Shinya
AU - Sakai, Daisuke
AU - Sugimoto, Naotoshi
AU - Matsumoto, Koji
AU - Goto, Isao
AU - Yamamoto, Nobuyuki
AU - Fukuoka, Masahiro
AU - Nakagawa, Kazuhiko
PY - 2013/12
Y1 - 2013/12
N2 - Background Carcinomas of unknown primary site (CUPs) are heterogeneous tumors associated with a poor prognosis. This phase II trial was designed to evaluate the efficacy and safety of a novel combination chemotherapy of S-1 and cisplatin (CDDP) in patients with CUP. Patients and Methods Patients with previously untreated CUPs were eligible for this trial. The treatment schedule consisted of oral S-1 (40 mg/m2) twice a day on days 1-21, and intravenous CDDP (60 mg/m2) on day 8. This schedule was repeated every 5 weeks. Results A total of 46 patients were enrolled. The overall response rate and the disease control rate were 41.3 % and 80.4 %, respectively. The median overall survival time was 17.4 months. Grade 3/4 neutropenia, thrombocytopenia, and febrile neutropenia occurred in 28.3 %, 13.0 %, and 2.2 % of the patients, respectively. Conclusion CDDP plus S-1 combination chemotherapy is well tolerated and active first-line empiric therapies for patients with CUP.
AB - Background Carcinomas of unknown primary site (CUPs) are heterogeneous tumors associated with a poor prognosis. This phase II trial was designed to evaluate the efficacy and safety of a novel combination chemotherapy of S-1 and cisplatin (CDDP) in patients with CUP. Patients and Methods Patients with previously untreated CUPs were eligible for this trial. The treatment schedule consisted of oral S-1 (40 mg/m2) twice a day on days 1-21, and intravenous CDDP (60 mg/m2) on day 8. This schedule was repeated every 5 weeks. Results A total of 46 patients were enrolled. The overall response rate and the disease control rate were 41.3 % and 80.4 %, respectively. The median overall survival time was 17.4 months. Grade 3/4 neutropenia, thrombocytopenia, and febrile neutropenia occurred in 28.3 %, 13.0 %, and 2.2 % of the patients, respectively. Conclusion CDDP plus S-1 combination chemotherapy is well tolerated and active first-line empiric therapies for patients with CUP.
UR - http://www.scopus.com/inward/record.url?scp=84888645574&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84888645574&partnerID=8YFLogxK
U2 - 10.1007/s10637-013-0014-0
DO - 10.1007/s10637-013-0014-0
M3 - Article
C2 - 23975509
AN - SCOPUS:84888645574
SN - 0167-6997
VL - 31
SP - 1568
EP - 1572
JO - Investigational New Drugs
JF - Investigational New Drugs
IS - 6
ER -